NO991560L - PDE IV-inhiberende 2-cyanoiminoimidazol-derivater - Google Patents

PDE IV-inhiberende 2-cyanoiminoimidazol-derivater

Info

Publication number
NO991560L
NO991560L NO991560A NO991560A NO991560L NO 991560 L NO991560 L NO 991560L NO 991560 A NO991560 A NO 991560A NO 991560 A NO991560 A NO 991560A NO 991560 L NO991560 L NO 991560L
Authority
NO
Norway
Prior art keywords
pde
inhibiting
cyanoiminoimidazole
derivatives
cyanoiminoimidazole derivatives
Prior art date
Application number
NO991560A
Other languages
English (en)
Other versions
NO312960B1 (no
NO991560D0 (no
Inventor
Eddy Jean Edgard Freyne
Francisco Javi Fernsndez-Gadea
Josu Ignacio Andrus-Gil
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO991560D0 publication Critical patent/NO991560D0/no
Publication of NO991560L publication Critical patent/NO991560L/no
Publication of NO312960B1 publication Critical patent/NO312960B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO19991560A 1996-10-02 1999-03-30 PDE IV-inhiberende 2-cyanoiminoimidazol-derivater NO312960B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02
PCT/EP1997/005322 WO1998014432A1 (en) 1996-10-02 1997-09-24 Pde iv inhibiting 2-cyanoiminoimidazole derivatives

Publications (3)

Publication Number Publication Date
NO991560D0 NO991560D0 (no) 1999-03-30
NO991560L true NO991560L (no) 1999-06-02
NO312960B1 NO312960B1 (no) 2002-07-22

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991560A NO312960B1 (no) 1996-10-02 1999-03-30 PDE IV-inhiberende 2-cyanoiminoimidazol-derivater

Country Status (30)

Country Link
US (1) US6051718A (no)
EP (1) EP0934280B1 (no)
JP (1) JP3068208B2 (no)
KR (1) KR100520002B1 (no)
CN (1) CN1106387C (no)
AR (1) AR008875A1 (no)
AT (1) ATE236884T1 (no)
AU (1) AU719561B2 (no)
BG (1) BG64278B1 (no)
BR (1) BR9712256B1 (no)
CA (1) CA2267322C (no)
CY (1) CY2380B1 (no)
CZ (1) CZ297474B6 (no)
DE (1) DE69720757T2 (no)
DK (1) DK0934280T3 (no)
EE (1) EE03825B1 (no)
ES (1) ES2196308T3 (no)
HU (1) HU225158B1 (no)
IL (2) IL129298A0 (no)
MY (1) MY116980A (no)
NO (1) NO312960B1 (no)
NZ (1) NZ334971A (no)
PL (1) PL194673B1 (no)
PT (1) PT934280E (no)
RU (1) RU2180902C2 (no)
SI (1) SI0934280T1 (no)
SK (1) SK285878B6 (no)
TR (1) TR199900732T2 (no)
UA (1) UA62939C2 (no)
WO (1) WO1998014432A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4778612B2 (ja) 1998-04-01 2011-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐｄｅｉｖ阻害ピリジン誘導体
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
RU2270192C2 (ru) * 2001-04-19 2006-02-20 Эйсай Ко., Лтд. Производные 2-иминопирролидина
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
US20040220227A1 (en) * 2001-07-11 2004-11-04 Shinji Ina Remedies for allergic eye diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
PT1908463E (pt) 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
EP1602646A4 (en) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2985787A1 (en) * 2012-06-07 2013-12-12 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
IL106517A0 (en) * 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
DK0672031T3 (da) * 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
WO1995005386A1 (en) * 1993-08-19 1995-02-23 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JP3056788B2 (ja) * 1994-06-24 2000-06-26 ユーロ−セルティーク，エス．エイ． ホスホジエステラーゼｉｖの阻害化合物および阻害方法
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
ATE236884T1 (de) 2003-04-15
PT934280E (pt) 2003-08-29
PL332573A1 (en) 1999-09-27
AR008875A1 (es) 2000-02-23
CN1232456A (zh) 1999-10-20
AU719561B2 (en) 2000-05-11
BG64278B1 (bg) 2004-08-31
SK285878B6 (sk) 2007-10-04
MY116980A (en) 2004-04-30
JP2000503678A (ja) 2000-03-28
NO312960B1 (no) 2002-07-22
BR9712256A (pt) 1999-08-24
WO1998014432A1 (en) 1998-04-09
CZ102899A3 (cs) 1999-07-14
US6051718A (en) 2000-04-18
EE9900112A (et) 1999-10-15
CN1106387C (zh) 2003-04-23
HUP9904063A3 (en) 2000-11-28
CY2380B1 (en) 2004-06-04
RU2180902C2 (ru) 2002-03-27
BG103220A (en) 1999-11-30
JP3068208B2 (ja) 2000-07-24
DE69720757D1 (de) 2003-05-15
NZ334971A (en) 2000-09-29
HK1020344A1 (en) 2000-04-14
EP0934280A1 (en) 1999-08-11
CA2267322C (en) 2007-11-06
IL129298A0 (en) 2000-02-17
BR9712256B1 (pt) 2011-04-19
EE03825B1 (et) 2002-08-15
PL194673B1 (pl) 2007-06-29
NO991560D0 (no) 1999-03-30
CZ297474B6 (cs) 2006-12-13
SK34499A3 (en) 2000-04-10
CA2267322A1 (en) 1998-04-09
SI0934280T1 (en) 2003-12-31
EP0934280B1 (en) 2003-04-09
HUP9904063A2 (hu) 2000-09-28
UA62939C2 (uk) 2004-01-15
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
ES2196308T3 (es) 2003-12-16
DE69720757T2 (de) 2004-03-04
IL129298A (en) 2006-04-10
DK0934280T3 (da) 2003-07-21
AU4779297A (en) 1998-04-24
HU225158B1 (en) 2006-07-28
KR100520002B1 (ko) 2005-10-13

Similar Documents

Publication Publication Date Title
ATE215950T1 (de) Carbolinderivate
DK0901474T3 (da) Arylpyrimidinderivater
ATE261942T1 (de) 6-phenylpyridinderivate
ATE236155T1 (de) Naphthyridin-derivate
ATE235220T1 (de) Resorcinderivate
DK1005446T3 (da) N-aroylphenylalaninderivater
ID22781A (id) Turunan-turunan nikotinamida
DE69817186D1 (de) Diaminorhodamin-derivate
NO981946D0 (no) Imidazoquinazolin-derivater
PT934280E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
ATE255098T1 (de) Substituierte chromanderivate
DE69841086D1 (de) 5-Deoxy-Cytidin-Derivate
ATE255099T1 (de) Substituierte chromanderivate
ZA978809B (en) PDE IV inhibiting 2-cyanoiminoimidazole derivatives
EE9900182A (et) 2-metoksüfenüülpiperasiini derivaadid
DK0966437T3 (da) 5-Aroylnaphthalenderivater
DK1068194T3 (da) PDE IV-hæmmende pyridinderivater
DE69829682D1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin-derivate
DE69828780D1 (de) Amidinocamptpthecin-derivate
DE69710921D1 (de) Heterocyclische substituierte pyrrolidinamid-derivate
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat
FI965181A7 (fi) Polyalkoholi-peptidijohdannaiset
ATA73396A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate
ATA69896A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate

Legal Events

Date Code Title Description
MK1K Patent expired